Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381125615> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- W4381125615 abstract "<h3>Introduction</h3> Skin disorders as extra-intestinal manifestations of inflammatory bowel disease (IBD) are well recognised. In addition, contribution of drugs used in IBD in development of skin cancers is now fully understood. However, there are increasing reports of drug induced immune skin disorders resulting from or contributed by anti TNF agents. We aim to describe the aetiology, manifestations and therapeutic approaches of anti TNF induced skin eruptions from a large tertiary centre cohort. <h3>Methods</h3> A prospective database of IBD patients receiving biologics for IBD was interrogated for those who developed skin eruptions following initiation of anti-TNF therapy. We excluded patients who had pre-existing skin manifestations. All patients had dermatological expert review and confirmation of diagnosis as drug induced skin disorder. We collected their disease characteristics, time interval from initiation of biologics to development of skin disorder, the putative causative agent and the treatment of the skin lesions. <h3>Results</h3> Eighty-four patients (5%) among 1498 patients (median age= 32 years, Female 53, male 31) who received at least one dose of biologics developed a drug induced immune skin disorder. Median duration to development of skin lesions was 12 months. Anti TNF agents were responsible for 88.5% of the skin lesions with the commonest lesions being psoriasiform lesions in 53 (63%) patients. In our cohort, the psoriasiform lesions were more prevalent in patients who used biosimilar anti-TNF agents compared to the originator agent (45 vs 4). Forty- eight patients required cessation of anti TNF agents because of skin eruptions. Thirty-six of these were switched to ustekinumab with resolution of skin eruptions in 35 patients. <h3>Conclusions</h3> Anti TNF induced psoriasiform skin lesions are not uncommon and appear to be more prevalent in the biosimilar era. Half of these patients will need treatment switch; ustekinumab appears to be an effective option in these patients." @default.
- W4381125615 created "2023-06-19" @default.
- W4381125615 creator A5009795571 @default.
- W4381125615 creator A5046490863 @default.
- W4381125615 creator A5071921893 @default.
- W4381125615 date "2023-06-01" @default.
- W4381125615 modified "2023-09-27" @default.
- W4381125615 title "P125 Anti TNF induced psoriasiform skin eruptions are increasing in the biosimilar era" @default.
- W4381125615 doi "https://doi.org/10.1136/gutjnl-2023-bsg.196" @default.
- W4381125615 hasPublicationYear "2023" @default.
- W4381125615 type Work @default.
- W4381125615 citedByCount "0" @default.
- W4381125615 crossrefType "proceedings-article" @default.
- W4381125615 hasAuthorship W4381125615A5009795571 @default.
- W4381125615 hasAuthorship W4381125615A5046490863 @default.
- W4381125615 hasAuthorship W4381125615A5071921893 @default.
- W4381125615 hasConcept C126322002 @default.
- W4381125615 hasConcept C137627325 @default.
- W4381125615 hasConcept C16005928 @default.
- W4381125615 hasConcept C2778260677 @default.
- W4381125615 hasConcept C2779134260 @default.
- W4381125615 hasConcept C2780564577 @default.
- W4381125615 hasConcept C59491497 @default.
- W4381125615 hasConcept C71924100 @default.
- W4381125615 hasConcept C72563966 @default.
- W4381125615 hasConceptScore W4381125615C126322002 @default.
- W4381125615 hasConceptScore W4381125615C137627325 @default.
- W4381125615 hasConceptScore W4381125615C16005928 @default.
- W4381125615 hasConceptScore W4381125615C2778260677 @default.
- W4381125615 hasConceptScore W4381125615C2779134260 @default.
- W4381125615 hasConceptScore W4381125615C2780564577 @default.
- W4381125615 hasConceptScore W4381125615C59491497 @default.
- W4381125615 hasConceptScore W4381125615C71924100 @default.
- W4381125615 hasConceptScore W4381125615C72563966 @default.
- W4381125615 hasLocation W43811256151 @default.
- W4381125615 hasOpenAccess W4381125615 @default.
- W4381125615 hasPrimaryLocation W43811256151 @default.
- W4381125615 hasRelatedWork W2799928618 @default.
- W4381125615 hasRelatedWork W2945043364 @default.
- W4381125615 hasRelatedWork W2955056766 @default.
- W4381125615 hasRelatedWork W3159932183 @default.
- W4381125615 hasRelatedWork W4200534430 @default.
- W4381125615 hasRelatedWork W4220693647 @default.
- W4381125615 hasRelatedWork W4294718754 @default.
- W4381125615 hasRelatedWork W4362578247 @default.
- W4381125615 hasRelatedWork W4376598430 @default.
- W4381125615 hasRelatedWork W4385476933 @default.
- W4381125615 isParatext "false" @default.
- W4381125615 isRetracted "false" @default.
- W4381125615 workType "article" @default.